Clinical trials registration
Not applicable. This was a demonstration project for CMS, not a clinical trial.
1. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol . Jan 2010;85(1):77-8. doi:10.1002/ajh.21570
2. Hassell KL. Population estimates of sickle cell disease in the U.S.Am J Prev Med . Apr 2010;38(4 Suppl):S512-21. doi:10.1016/j.amepre.2009.12.022
3. Brodsky MA, Rodeghier M, Sanger M, et al. Risk Factors for 30-Day Readmission in Adults with Sickle Cell Disease. Am J Med . May 2017;130(5):601 e9-601 e15. doi:10.1016/j.amjmed.2016.12.010
4. Cronin RM, Dorner TL, Utrankar A, et al. Increased Patient Activation Is Associated with Fewer Emergency Room Visits and Hospitalizations for Pain in Adults with Sickle Cell Disease. Pain Med . Aug 1 2019;20(8):1464-1471. doi:10.1093/pm/pny194
5. Cronin RM, Yang M, Hankins JS, et al. Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease. Hematology . Dec 2020;25(1):229-240. doi:10.1080/16078454.2020.1780737
6. Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.Am J Hematol . Apr 2008;83(4):263-70. doi:10.1002/ajh.21049
7. Gehrie EA, Ness PM, Bloch EM, Kacker S, Tobian AAR. Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease. Transfusion . Sep 2017;57(9):2267-2276. doi:10.1111/trf.14212
8. Kamble S, Telen MJ, Dinan MA, Grussemeyer CA, Reed SD. Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement. Am J Hematol . Jan 2010;85(1):79-81. doi:10.1002/ajh.21576
9. Weatherall D, Hofman K, Rodgers G, Ruffin J, Hrynkow S. A case for developing North-South partnerships for research in sickle cell disease.Blood . Feb 1 2005;105(3):921-3. doi:10.1182/blood-2004-06-2404
10. Gupta N, Mocumbi A, Arwal SH, et al. Prioritizing Health-Sector Interventions for Noncommunicable Diseases and Injuries in Low- and Lower-Middle Income Countries: National NCDI Poverty Commissions.Glob Health Sci Pract . Sep 30 2021;9(3):626-639. doi:10.9745/GHSP-D-21-00035
11. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers . Mar 15 2018;4:18010. doi:10.1038/nrdp.2018.10
12. Chang AK, Ginter Summarell CC, Birdie PT, Sheehan VA. Genetic modifiers of severity in sickle cell disease. Clin Hemorheol Microcirc . 2018;68(2-3):147-164. doi:10.3233/CH-189004
13. Hsu LL, Green NS, Donnell Ivy E, et al. Community Health Workers as Support for Sickle Cell Care. Am J Prev Med . Jul 2016;51(1 Suppl 1):S87-98. doi:10.1016/j.amepre.2016.01.016
14. Peterson EE, Salemi JL, Dongarwar D, Salihu HM. Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost. Eur J Pediatr . Nov 2020;179(11):1701-1710. doi:10.1007/s00431-020-03656-x
15. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study. J Health Econ Outcomes Res . 2020;7(1):52-60. doi:10.36469/jheor.2020.12852
16. Habara A, Steinberg MH. Minireview: Genetic basis of heterogeneity and severity in sickle cell disease. Exp Biol Med (Maywood) . Apr 2016;241(7):689-96. doi:10.1177/1535370216636726
17. Saraf SL, Akingbola TS, Shah BN, et al. Associations of alpha-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. Blood Adv . Apr 25 2017;1(11):693-698. doi:10.1182/bloodadvances.2017005231
18. Marshall K, Howell S, Badaloo A, Reid M, McFarlane-Anderson N, McKenzie C. Exploring putative genetic determinants of inter-individual phenotypic heterogeneity in sickle cell disease: A cross-sectional Jamaican cohort-based study. Blood Cells Mol Dis . Nov 2018;73:1-8. doi:10.1016/j.bcmd.2018.08.001
19. Brennan-Cook J, Bonnabeau E, Aponte R, Augustin C, Tanabe P. Barriers to Care for Persons With Sickle Cell Disease: The Case Manager’s Opportunity to Improve Patient Outcomes. Prof Case Manag . Jul/Aug 2018;23(4):213-219. doi:10.1097/ncm.0000000000000260
20. Edge NB. Breaking the Cycle: Care Coordination Interventions and Sickle Cell Readmissions. Prof Case Manag . Jan-Feb 01 2022;27(1):12-18. doi:10.1097/NCM.0000000000000526
21. Glassberg JA, Wang J, Cohen R, Richardson LD, DeBaun MR. Risk factors for increased ED utilization in a multinational cohort of children with sickle cell disease. Acad Emerg Med . Jun 2012;19(6):664-72. doi:10.1111/j.1553-2712.2012.01364.x
22. Hsu LL, Fan-Hsu J. Evidence-based dental management in the new era of sickle cell disease: A scoping review. J Am Dent Assoc . Sep 2020;151(9):668-677 e9. doi:10.1016/j.adaj.2020.05.023
23. Glassgow AE, Martin MA, Caskey R, et al. An innovative health-care delivery model for children with medical complexity. J Child Health Care . Sep 2017;21(3):263-272. doi:10.1177/1367493517712063
24. Tyris J, Keller S, Parikh K. Social Risk Interventions and Health Care Utilization for Pediatric Asthma: A Systematic Review and Meta-analysis. JAMA Pediatr . Feb 1 2022;176(2):e215103. doi:10.1001/jamapediatrics.2021.5103
25. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental determinants of severity in sickle cell disease. Haematologica . Sep 2015;100(9):1108-16. doi:10.3324/haematol.2014.120030
26. Piel FB, Tewari S, Brousse V, et al. Associations between environmental factors and hospital admissions for sickle cell disease.Haematologica . Apr 2017;102(4):666-675. doi:10.3324/haematol.2016.154245
27. Jonassaint CR, Jones VL, Leong S, Frierson GM. A systematic review of the association between depression and health care utilization in children and adults with sickle cell disease. Br J Haematol . Jul 2016;174(1):136-47. doi:10.1111/bjh.14023
28. Gustafson EL, Lakind D, Walden AL, Rusch D, Atkins MS. Engaging Parents in Mental Health Services: A Qualitative Study of Community Health Workers’ Strategies in High Poverty Urban Communities. Adm Policy Ment Health . Nov 2021;48(6):1019-1033. doi:10.1007/s10488-021-01124-8
29. Martin MA, Collazo GR, Frese WA, Glassgow AE. Oral Health Problems and Solutions in High-Risk Children and Young Adults. J Dent Child (Chic) . Sep 15 2018;85(3):125-132.
30. Minier M, Hirshfield L, Ramahi R, Glassgow AE, Fox K, Martin MA. Schools and Health: An Essential Partnership for the Effective Care of Children with Chronic Conditions. J Sch Health . Sep 2018;88(9):699-703. doi:10.1111/josh.12671
31. Martin MA, Perry-Bell K, Minier M, Glassgow AE, Van Voorhees BW. A Real-World Community Health Worker Care Coordination Model for High-Risk Children. Health Promot Pract . May 2019;20(3):409-418. doi:10.1177/1524839918764893
32. Bansa M, Glassgow AE, Martin M, et al. Development of a Community-Based Medical Neighborhood for Children with Chronic Conditions. Prog Community Health Partnersh . 2019;13(1):83-95. doi:10.1353/cpr.2019.0011
33. Caskey R, Moran K, Touchette D, et al. Effect of Comprehensive Care Coordination on Medicaid Expenditures Compared With Usual Care Among Children and Youth With Chronic Disease: A Randomized Clinical Trial.JAMA Netw Open . Oct 2 2019;2(10):e1912604. doi:10.1001/jamanetworkopen.2019.12604
34. Glassgow AE, Gerges M, Atkins M, et al. Exploring Racial Disparities in Mental Health Diagnoses and Neighborhood Disorganization Among an Urban Cohort of Children and Adolescents with Chronic Medical Conditions. Health Equity . 2019;3(1):604-611. doi:10.1089/heq.2019.0085
35. Deb P, Norton EC. Modeling Health Care Expenditures and Use.Annu Rev Public Health . Apr 1 2018;39:489-505. doi:10.1146/annurev-publhealth-040617-013517
36. Molenberghs G, Verbeke G. Models for Discrete Longitudinal Data . 1 ed. Springer Series in Statistics. Springer; 2005:687.
37. Piulachs X, Andrinopoulou ER, Guillen M, Rizopoulos D. A Bayesian joint model for zero-inflated integers and left-truncated event times with a time-varying association: Applications to senior health care.Stat Med . Jan 15 2021;40(1):147-166. doi:10.1002/sim.8767
38. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. Journal of the American Statistical Association . 1955;50(272):1096-1121.
39. Holdford D, Vendetti N, Sop DM, Johnson S, Smith WR. Indirect Economic Burden of Sickle Cell Disease. Value Health . Aug 2021;24(8):1095-1101. doi:10.1016/j.jval.2021.02.014
40. Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv . May 16 2022;doi:10.1182/bloodadvances.2021006281
41. Raphael JL, Dietrich CL, Whitmire D, Mahoney DH, Mueller BU, Giardino AP. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer . Feb 2009;52(2):263-7. doi:10.1002/pbc.21781
42. Rattler TL, Walder AM, Feng H, Raphael JL. Care Coordination for Children With Sickle Cell Disease: A Longitudinal Study of Parent Perspectives and Acute Care Utilization. Am J Prev Med . Jul 2016;51(1 Suppl 1):S55-61. doi:10.1016/j.amepre.2016.01.023
43. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA . Sep 10 2014;312(10):1033-48. doi:10.1001/jama.2014.10517